An observational study in Lower Limb Amputation, sponsored by Virginia Commonwealth University. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-21.
Sponsored by Virginia Commonwealth University · Observational
Despite high medical expenses (>$500K/patient), mobility improvements achieved during rehabilitation for people with lower limb amputation (LLA) fail to translate into improved real-world outcomes. Even with advances in prosthesis technology enabling faster gait speed, greater walking endurance, and improved mobility confidence, people with LLA report persistent dissatisfaction with real-world mobility, limited ability to walk in the community, and difficulty achieving recommended physical activity levels.
Real-world walking requires thinking and moving simultaneously (e.g., cognitive-motor dual-tasking), visually attending to the environment, and navigating varying terrain. In contrast, clinical mobility assessments are usually performed without additional visual or cognitive demands, in controlled environments, and on level surfaces. Current clinical tools used to assess ambulation progression during rehabilitation do not adequately assess these changes in people who have experienced LLA.
A step toward rectifying a critical gap in care for those with LLA by quantifying the effect of vision-based and non-vision-based cognitive-motor dual-tasking and high and low complexity terrain on gait speed and gaze behavior. Cognitive-motor dual-task assessment paradigms are well-established in other populations and often used to better approximate real-world walking demands. However, the type of cognitive task used is an important factor. The most common methods for dual-task assessment in people with LLA are limited to cognitive tasks lacking overt visual attention (e.g., serial subtraction - performing repeated subtractions from a given starting number).Although walking while performing non-vision-based cognitive tasks results in slower gait speed than single-task walking, this type of task has limited ecological validity and the observed dual-task performances have not been associated with real-world walking outcomes.
Performing vision-based cognitive-motor dual-tasks is particularly important for people with LLA. Due to lost somatosensory input from the amputated limb, the central nervous system increases dependence on visual input for sensorimotor integration. As a result, people with LLA report needing to "concentrate on every step", and affix their gaze on each subsequent step compared to 3 steps ahead like adults without LLA.
Current clinical assessments fail to detect impairments during mobility tasks requiring visual attention in complex environments. The lack of understanding of the interaction between visual attention and complex environment precludes a comprehensive mobility assessment, allows undetected impairments to persist, and limits translation of rehabilitation gains into improved real-world mobility outcomes.
We will compare gait speed (Aim1) and gaze behavior with eye-tracking glasses (Aim 2) during vision-based (visual puzzles) and non-vision-based (serial subtraction) cognitive-motor dual-tasking while walking on low and high complexity terrain in people with LLA (n=20) and matched controls (n=10).
Exclusion Criteria:
Participants in the control group must meet the non-amputation-related criteria noted above, be within ±2 years and the same biological sex as their paired participants with LLA.
20 participants with below knee amputation.
Other: Comprehensive assessment of walking patterns and functional mobility · Other: Comprehensive assessment of eye movements during walking · Other: Questionnaire Assessments completed
10 sex- and age-matched control participants.
Other: Comprehensive assessment of walking patterns and functional mobility · Other: Comprehensive assessment of eye movements during walking · Other: Questionnaire Assessments completed
Assessment of accelerometry: Daily duration (minutes) of sitting, standing, stepping, Daily step count, Daily walking bouts stepping cadence, Timed Up and Go and Two-minute Walk Test
Comprehensive assessment of eye movements during walking including Target Fixation Time (seconds; %) and Number of fixations
The following assessments will be completed: World health organization disability assessment schedule 2.0 (WHODAS), and Activities Specific Balance Confidence Scale.
Gait Analysis-Walking Speed
Measure walking speed meters/second. Captured during dual-task and single-task walking, it is used to measure motor performance. Normal Speed: Healthy adults usually walk at 1.2 to 1.4 meters per second.Fall Risk: A speed below 1.0 meter per second shows a higher risk for falls.Frailty Warning: A speed below 0.6 to 0.8 meters per second suggests a high risk of functional decline or disability.
Time frame: Visit 1 and visit 2 (which will take place 10-14 days after visit 1)
Gait Analysis-Stride Length
Measure the stride length in meters. stride length is the total distance covered during one full cycle of walking or running with the same foot. It measures the space from where one foot touches the ground to when that exact same foot touches the ground again.
Time frame: Visit 1 and visit 2 (which will take place 10-14 days after visit 1)
Gait Analysis-Stride length asymmetry
Assess Stride length asymmetry is an imbalance where the distance covered by the right and left steps differs. Symmetry Index (SI): Compares spatial step metrics or temporal single-limb support times between limbs.Percentage difference: Calculated by contrasting mean left and right step values; values exceeding 10% typically indicate notable dysfunction.
Time frame: Visit 1 and visit 2 (which will take place 10-14 days after visit 1)
Cognitive Task Performance Cognitive Task Performance
Accuracy (percentage correct) of each cognitive task. This reflects cognitive performance and is measured in both dual-task and single-task conditions.
Time frame: Visit 1 and visit 2 (which will take place 10-14 days after visit 1)
Cognitive Task Performance
Measure Response time (milliseconds)
Time frame: Visit 1 and visit 2 (which will take place 10-14 days after visit 1)
Functional Mobility (Two-minute Walk Test)
Two-minute Walk Test measures the total distance a person can walk on a flat, hard surface within two minutes. It evaluates functional mobility, submaximal endurance, and self-paced walking capacity in adults. Recorded to the nearest meter or foot using a measuring wheel, and lap count.
Time frame: Visit 1 and visit 2 (which will take place 10-14 days after visit 1)
Functional Mobility (Timed Up and Go)
Timed Up and Go (TUG) test measures functional mobility, dynamic balance, and fall risk by timing how fast a person stands from a chair, walks 3 meters (10 feet), turns around, walks back, and sits down. Under 10-12 seconds: Normal, independent mobility with low fall risk.12-20 seconds: Moderate risk of falling or subtle mobility issues; requires further evaluation.Over 14-20 seconds: High risk for falls; often indicates difficulty moving outside alone or a need for assistive devices.
Time frame: Visit 1
Eye Tracking (Target Fixation Time)
Target Fixation Time (seconds; %), The length of time the eye remains relatively still on a target to process detail, reflecting visual attention.
Time frame: Visit 1 and visit 2 (which will take place 10-14 days after visit 1)
Eye Tracking (Number of fixations)
Number of fixations is a core metric measuring how many times a person's eyes pause and focus on a specific area or object. High Fixation Count: indicates frequent attention on an area or element. Low Fixation Count: Means an element was quickly passed over, easily understood, or ignored.
Time frame: Visit 1 and visit 2 (which will take place 10-14 days after visit 1)
Patient Reported Outcomes (Houghton Scale)
The Houghton Scale assesses a person's confidence and ability in using their prosthesis safely and effectively during everyday mobility tasks. The Houghton Scale is a self-administered, 4-item questionnaire used to assess the functional use of a prosthesis by individuals with lower-limb amputations.It measures how often a patient wears their prosthesis, the types of activities they perform with it, and their perceived stability in various outdoor environments. Total scores range from 0 to 12, with higher scores indicating greater prosthesis use and independence
Time frame: Visit 1
Patient Reported Outcomes (PEQ - Mobility subscale)
PEQ - Mobility subscale is the The Prosthesis Evaluation Questionnaire - Mobility subscale, captures a person's self reported ability to move and perform daily activities while using their prosthesis. It uses a 5-point ordinal scale (0-4). 0: Not able or hardly able to 4: No problem or almost fully able. The total scale ranges from 0 to 48. A higher score indicates greater mobility.
Time frame: Visit 1
Patient Reported Outcomes (WHODAS)
WHODAS The World health organization disability assessment schedule 2.0 (WHODAS) evaluates how health conditions impact a person's functioning and participation across major life domains over the past 30 days. Items are rated on a 5-point Likert scale: None (0), Mild (1), Moderate (2), Severe (3), and Extreme or Cannot Do (4). While no universal "cut-off" exists, scores placing a patient in the top 10% of the population distribution-roughly \>10 for the 12-item simple score or \>41 for the 36-item version-likely indicate significant impairment.
Time frame: Visit 1
Patient Reported Outcomes (Activities Specific Balance Confidence Scale)
Activities Specific Balance Confidence Scale is a self-report instrument used to measure an individual's confidence in maintaining balance while performing 16 various daily activities. Unlike performance-based tests, it captures the patient's perceived ability to avoid falling or becoming unsteady.Patients rate their confidence for each item on a scale from 0% (no confidence) to 100% (complete confidence). The higher the score,the higher the function and physical activity (range \> 80% high function, 50% - 80% moderate function and \< 50% low function.
Time frame: Visit 1
Accelerometry (Daily duration of sitting, standing, stepping)
Daily duration (minutes) of sitting, standing, and stepping reported as an aggregate mean.
Time frame: Between Visit 1 and 2 (which is 10-14 days after visit 1)
Accelerometry (Daily step count)
Daily step count will be measured and reported as an aggregate mean.
Time frame: Between Visit 1 and 2 (which is 10-14 days after visit 1)
Accelerometry (Daily walking bouts stepping cadence)
Daily walking bouts stepping cadence will be reported as an aggregate mean
Time frame: Between Visit 1 and 2 (which is 10-14 days after visit 1)
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Virginia Commonwealth University